Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

Tuuli Ranki, Sari Pesonen, Akseli Hemminki, +23

Journal for ImmunoTherapy of Cancer

Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity

Robert Strauss, Zongyi Li, Ying Liu, +11

PLoS ONE

Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Sari Pesonen, Iulia Diaconu, Lotta Kangasniemi, +17

Cancer Research

ImmunologyImmunoeditingImmunodominanceCd4 T Cell ResponsesImmunotherapeutics +21

Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors

Petri Nokisalmi, Sari Pesonen, Sophie Escutenaire, +18

Clinical Cancer Research

Tissue-Specific Promoters Active in CD44+CD24−/low Breast Cancer Cells

Gerd Bauerschmitz, Tuuli Ranki, Lotta Kangasniemi, +12

Cancer Research

Oncolytic Adenoviruses Kill Breast Cancer Initiating CD44+CD24–/Low Cells

Minna Eriksson, Kilian Guse, Gerd Bauerschmitz, +8

Molecular Therapy

Cancer-associated VirusMedicineStem CellsImmunologyCancer Cell Biology +10

Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer

Otto Hemminki, Iulia Diaconu, Vincenzo Cerullo, +10

Molecular Therapy

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

Sari Pesonen, Petri Nokisalmi, Sophie Escutenaire, +19

Gene Therapy

MedicinePathologyRefractory Solid TumorsOncologyRadiation Oncology +4

Oncolytic adenovirus based on serotype 3

Otto Hemminki, Gerd Bauerschmitz, Silvio Hemmi, +10

Cancer Gene Therapy

PathologyVirologyMedicineViral GeneticsOncolytic Adenovirus +1

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8⁺T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer

Lotta Vassilev, Tuuli Ranki, Timo Joensuu, +22

OncoImmunology